Literature DB >> 27465469

Re: Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.

Ozgu Aydogdu1, Ibrahim Halil Bozkurt2, Tarik Yonguc2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27465469     DOI: 10.1007/s00345-016-1904-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  10 in total

1.  Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC).

Authors:  Michał Hrab; Karolina Olek-Hrab; Andrzej Antczak; Zbigniew Kwias; Tomasz Milecki
Journal:  Rep Pract Oncol Radiother       Date:  2013-07-26

2.  Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis.

Authors:  Rodney H Breau; R Jeffrey Karnes; Sara A Farmer; Prabin Thapa; Ilias Cagiannos; Christopher Morash; Igor Frank
Journal:  BJU Int       Date:  2013-11-27       Impact factor: 5.588

Review 3.  Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review.

Authors:  Sven van den Bosch; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-06-01       Impact factor: 20.096

4.  Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study.

Authors:  T Grimm; A Buchner; B Schneevoigt; A Kretschmer; M Apfelbeck; M Grabbert; J F Jokisch; C G Stief; A Karl
Journal:  World J Urol       Date:  2015-09-16       Impact factor: 4.226

5.  Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.

Authors:  Atiqullah Aziz; Michael Rink; Georgios Gakis; Luis A Kluth; Christopher Dechet; Florian Miller; Wolfgang Otto; Michael Gierth; Stefan Denzinger; Christian Schwentner; Arnulf Stenzl; Margit Fisch; Maximilian Burger; Hans-Martin Fritsche
Journal:  Urol Int       Date:  2014-08-19       Impact factor: 2.089

6.  Bladder cancer.

Authors:  Peter E Clark; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Philippe E Spiess; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-04-01       Impact factor: 11.908

7.  The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.

Authors:  Boris Gershman; Daniel M Moreira; Matthew K Tollefson; Igor Frank; John C Cheville; Prabin Thapa; Robert F Tarrell; Robert Houston Thompson; Stephen A Boorjian
Journal:  Urol Oncol       Date:  2015-08-29       Impact factor: 3.498

8.  Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer.

Authors:  Christian Kersten; Johanna Louhimo; Annika Ålgars; Aleksi Lahdesmaki; Milada Cvancerova; Kristina Stenstedt; Caj Haglund; Ulf Gunnarsson
Journal:  Acta Oncol       Date:  2013-11       Impact factor: 4.089

9.  Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients.

Authors:  Liuyu Xu; Qingli Zhao; Shengliang Huang; Shun Li; Jin Wang; Qing Li
Journal:  Tumour Biol       Date:  2014-10-07

Review 10.  Anemia in malignancies: pathogenetic and diagnostic considerations.

Authors:  Balan Louis Gaspar; Prashant Sharma; Reena Das
Journal:  Hematology       Date:  2014-03-26       Impact factor: 2.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.